Back Back
Cell No. : Cell Name
RCB0665 : HFWT  update : 2022/03/30
CommentHuman cell line derived from Wilms' tumor. Expressing CA125 and TPA.
Comment from the depositor
Terms and conditionsNeed an approval of the approver. Academic basic research purpose only (excluding any type of commercial use, i.e., commercializing not only HFWT cells but also all the HFWT-originated commercially useful materials and methods such as the cellular components, products, genes, their derivatives, application methods, and the like.) .
approver's address
Cell-Medicine, Inc.
2-1-6 Sengen, Tsukuba, Ibaraki 305-0047 Japan
Dr.OHNO Tadao
Fax. +81-29-828-5592
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Ishiwata, Isamu (Ohno, Tadao)
Originator Ono, I. & Ishiwata, I. & Ishikawa, H.
Year of deposit 1991
Animal _human < Mammals
Genus Homo
Species sapiens
Gender Male
Age at sampling 5 months
Tissue kidney
Disease name Wilms' tumor
Classification cancer
Year of origin 1984
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_8691
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium HamF12 + 15% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) (-)
Isozyme LD, NP
Chromosome mode 44-92(50) : 44(2),45(8),46(35),47(3),92(2)/
STR(human) OK
Reference information Reference 5
User's Publication 5

To topTop
2719  Harada, Hideki, Saijo, Kaoru, Ishiwata, Isamu, Ohno, Tadao  A GFP-transfected HFWT cell line, GHINK-1, as a novel target for non-RI activated natural killer cytotoxicity assay.  Hum Cell  2004  17:43-8  PubMed ID: 15369136   DOI: 10.1111/j.1749-0774.2004.tb00019.x
859  Harada H, Watanabe S, Saijo K, Ishiwata I, Ohno T.  A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells  Exp Hematol  2004  32(7):614-21  PubMed ID: 15246157   DOI: 10.1016/j.exphem.2004.03.011
858  Oikawa T, Kawai K, Ishiwata I, Ohno T, Akaza H.   Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer  BJU Int  2003  92(9):1009-15  PubMed ID: 14632866   DOI: 10.1111/j.1464-410x.2003.04509.x
861  Harada H, Saijo K, Watanabe S, Tsuboi K, Nose T, Ishiwata I, Ohno T.  Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT  Jpn J Cancer Res  2002  93(3):313-9  PubMed ID: 11927014   DOI: 10.1111/j.1349-7006.2002.tb02174.x
1525  Ishiwata I, Ono I, Ishiwata C, Soma M, Nakaguchi T, Ohara K, Hirano M, Ishikawa H  Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo.  Exp Pathol  1991  41:1-9  PubMed ID: 1850701   DOI: 10.1016/s0232-1513(11)80040-x

To topTop
User's Publication
20687  Zhu Q, Zhan D, Yang Y, Chong Y, Xue H, Zhu P.  LINC00173 Promotes Wilms' Tumor Progression Through MGAT1-mediated MUC3A N-glycosylation.  Cell Cycle  2022    PubMed ID: 35491865   DOI: 10.1080/15384101.2022.2070399
20062  Zhu S, Zhang J, Gao X, Tang X, Cui Y, Li D, Jia W.  Silencing of long noncoding RNA MYLK-AS1 suppresses nephroblastoma via down-regulation of CCNE1 through transcription factor TCF7L2.  J Cell Physiol  2021    PubMed ID: 33438217   DOI: 10.1002/jcp.30259
12051  Zhu S, Zhang J, Cui Y, Tang X, Gao X, Li D, Jia W.  Long non-coding RNA HOXA11-AS upregulates Cyclin D2 to inhibit apoptosis and promote cell cycle progression in nephroblastoma by recruiting forkhead box P2.  Am J Cancer Res  2020    PubMed ID: 32064168  
18270  Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, Ariga T, Okita H, Koshinaga T, Oue T, Hinotsu S, Nakadate H, Horie H, Fukuzawa M, Kaneko Y.  Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor  Pediatr Blood Cancer  2012  59(3):499-505  PubMed ID: 22457227   DOI: 10.1002/pbc.24093
2762  Ishikawa, Eiichi, Tsuboi, Koji, Saijo, Kaoru, Harada, Hideki, Takano, Shingo, Nose, Tadao, Ohno, Tadao  Autologous natural killer cell therapy for human recurrent malignant glioma.  Anticancer Res  2004  24:1861-71  PubMed ID: 15274367  

Back Back Return Top Page